$1.11
-0.09 (-7.50%)
AVI BioPharma, Inc. (NASDAQ:AVII)
CAPS Rating:
A biopharmaceutical company developing therapeutic products principally based on third-generation NEUGENE antisense technology.
A biopharmaceutical company developing therapeutic products principally based on third-generation NEUGENE antisense technology.